Sleuth Studio
Customer Stories

How a top-10 pharma runs research across five teams in Studio

Sleuth is market intelligence infrastructure for whole pharma teams. At one top-10 pharma, five teams, from business development to R&D, bring their hardest questions to Studio and get back answers that were previously buried in the data.

A global top-10 pharma

How a top-10 pharma runs research across five teams in Studio

Download the full case study

Partner

Challenge

The people hired to make strategic decisions spent their time gathering data. Databases were thin on early and private companies, landscapes went stale within a week, and trackers were updated by hand.

Approach

Outcome

Each team brings its own questions to Studio. Landscapes get rerun when the field changes, and companies, assets, and vendors get checked before the first call.

The teams using Studio and the research they run

A grid of five teams (competitive intelligence, business development, search and evaluation, external innovation, and R&D and manufacturing) by the research each runs in Studio, with 25 people, 211 projects, and about 5 new projects a week.

Each team brings its own problem to Studio and leaves with an answer

Studio pulls every relevant drug, trial, deal, and company, then runs the analysis on top.

Which patients in this indication will matter most in five years, not just today?

Pulled 1,180 active trials and their patient populations, then modeled how each readout shifts the standard of care. If the late-stage trials succeed, a new group of patients who stop responding appears, and few programs are built for them.

Which of 400+ exhibitors at an event deserve one of our 20 meeting slots?

Matched each exhibitor to its pipeline, deals, and financing, then scored fit and readiness to partner. Six exhibitors were strong fits with unpartnered assets and no recent financing. Likely to deal soon.

Which UK investors back the kind of assets we want to in-license, and back them early?

Ranked 150 investors in UK biotech on portfolio assets in the team’s focus areas and how many pharma later licensed. The best fit wasn’t on the team’s list. The two firms it was weighing ranked fourth and eighth.

Is a partner’s asking price for a Phase 2 asset defensible?

The price was nearly double what similar deals paid. But buyers have paid that much for drugs that reached market first, and this one is on track to be the first pill in its class.

A Studio table comparing a Phase 2 asking price with licensing deals for similar drugs, beside 4,200 deals screened in 2 hours.

Which AI liver-toxicity vendors’ predictions hold up in real programs?

The most reliable vendor wasn’t the busiest. None of its partnered programs was stopped for liver safety, against about one in seven across the field.

A Studio record of AI liver-toxicity vendors and their partnered programs, beside 137 programs traced in 3 hours.

Five teams now do their research in Studio, so their time goes into the decisions instead of the data gathering.

Download
Use case

Set Studio up across your teams

Bring your own asset, target, or indication, and Sleuth builds the analysis for you.

More from Sleuth